News
BIOVF
47.35
NaN%
--
Swedish Orphan Biovitrum AB (0MTD) Receives a Buy from Berenberg Bank
TipRanks · 05/28 06:16
Sobi Earns Reiterated Buy as Tryngolza Data Strengthen Growth Outlook; SEK550 Price Target Maintained
TipRanks · 05/27 12:25
Sobi’s Tryngolza cuts pancreatitis risk 85% in severe hypertriglyceridemia trial analysis
TipRanks · 05/26 14:32
Kapoor Reiterates Buy on Sobi, Lifts Pozdeutinurad Success Odds and Raises 12-Month Price Target to SEK550 on Strong Phase 3 Gout Data
TipRanks · 05/22 14:25
Sobi Posts Positive Phase 3 Data for Gout Drug Pozdeutinurad
TipRanks · 05/22 00:41
Swedish Orphan Biovitrum initiated with a Buy at H.C. Wainwright
TipRanks · 05/07 03:15
Sobi AGM Backs Board, Incentive Plans and New Share Issue Mandate
TipRanks · 05/06 10:04
Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)
TipRanks · 05/01 01:50
Swedish Orphan Biovitrum AB (0MTD) Receives a Buy from Berenberg Bank
TipRanks · 04/29 06:55
Swedish Orphan Biovitrum AB GAAP EPS of SEK 3.81, revenue of SEK 4.52M
Seeking Alpha · 04/28 16:49
Sobi posts strong Q1 2026 as launches and pipeline deals power growth
TipRanks · 04/28 06:54
Berenberg Bank Keeps Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)
TipRanks · 04/14 05:37
Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO
NASDAQ · 04/10 14:00
Health Canada Approves Swedish Orphan Biovitrum's EMPAVELI In C3G And Primary IC-MPGN Kidney Disease
NASDAQ · 04/10 07:13
Sobi Calls 2026 AGM With In-Person and Postal Voting Options
TipRanks · 03/27 09:32
Swedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at Barclays
TipRanks · 02/24 17:10
Swedish Orphan Biovitrum price target raised to SEK 500 from SEK 470 at Berenberg
TipRanks · 02/23 18:00
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
TipRanks · 02/19 09:40
Sobi Sets Ambitious 2030 Target to Double Revenue on Wave of New Rare-Disease Launches
TipRanks · 02/18 09:18
Swedish Orphan upgraded to Outperform from Underperform at BNP Paribas
TipRanks · 02/10 10:00
More
Webull provides a variety of real-time BIOVF stock news. You can receive the latest news about Swedish Orphan Biovitrum Ab through multiple platforms. This information may help you make smarter investment decisions.
About BIOVF
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.